Gomez M, et al. - Researchers investigated whether switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing regimen is related to weight changes in a human immunodeficiency virus (HIV)-positive adult cohort. For this purpose, data gathered from routine care in a university hospital in Munich, Germany, between July 2015 and June 2017 was retrospectively analyzed. The investigators compared weight/body mass index progression within 1 year after initiation of either TDF or TAF, and subsequently analyzed weight measurements within individuals changing from a TDF- to a TAF-containing antiretroviral regimen by means of a repeated measurements general linear model. Participants showed a mean (± standard deviation) percentual weight increase of 3.17 ± 0.21 after 360 days of initiating TAF vs 0.55 ± 0.17 after 360 days of initiating TDF. Findings thus supported the correlation of changing from a TDF- to a TAF-containing regimen with weight gain in this retrospectively analyzed real-world cohort.